Search
Ranolazine
go.drugbank.com/drugs/DB00243ApprovedInvestigational[L3580] With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.[L5440] … Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities.
Evinacumab
go.drugbank.com/drugs/DB15354ApprovedInvestigationalEvinacumab is novel in its mechanism of action compared with other lipid-lowering therapies and therefore provides a unique and synergistic therapeutic option in the treatment of HoFH. … The ANGPTL family of proteins serve a number of physiologic functions - including involvement in the regulation of lipid metabolism - which have made them desirable therapeutic targets in recent years.
Ravulizumab
go.drugbank.com/drugs/DB11580ApprovedInvestigationalRavulizumab is a potent and selective complement 5 (C5) inhibitor. It is a humanized monoclonal IgG2/4 kappa antibody produced in Chinese hamster ovary (CHO) cells. … [A244460] It works by blocking terminal complement-mediated inflammation, cell activation, and cell lysis in blood disorders associated with the destruction of red blood cells, thrombosis, and impaired
Cilostazol
go.drugbank.com/drugs/DB01166ApprovedInvestigationalCilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia … It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions.
Categories: Compounds used in a research, industrial, or household settingProducts: CILOSTAZOL AL 50MG TAB, CILOSTAZOL AL 100MG TABTrospium
go.drugbank.com/drugs/DB00209ApprovedInvestigational[L6208] Trospium is manufactured by _Indevus Pharmaceutical Inc._ and was granted FDA approval in 2007.[L6211] … Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably.
Clioquinol
go.drugbank.com/drugs/DB04815ApprovedVet approvedWithdrawnClioquinol was withdrawn in 1983 due to neurotoxicity.
Mixtures: CORTINOL D, Ala QuinEfanesoctocog alfa
go.drugbank.com/drugs/DB16662ApprovedInvestigationalepisodes in patients with hemophilia A. … [L45379] The use of FVIII replacement products is beneficial in patients with hemophilia A; however, their quality of life can be affected due to frequent doses.
Oxilofrine
go.drugbank.com/drugs/DB11610ApprovedOxilofrine is used in combination with [DB11609] as an antitussive. It is currently marketed in Canada by Valeant under the tradename Cophylac.
Linzagolix
go.drugbank.com/drugs/DB17083ApprovedInvestigationalLinzagolix is a non-peptide, selective antagonist of the gonadotropin-releasing hormone (GnRH) receptor. … [A253667] Linzagolix was approved for use in the European Union in June 2022 for the management of symptoms caused by uterine fibroids.[L43627]
Synonyms: 3-(5-((2,3-difluoro-6-methoxyphenyl)methoxy)-2-fluoro-4-methoxyphenyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno(3,4-d)pyrimidine-5-carboxylic acid, Thieno(3,4-d)pyrimidine-5-carboxylic acid, 3-(5-((2,3-difluoro-6-methoxyphenyl)methoxy)-2-fluoro-4-methoxyphenyl)-1,2,3,4-tetrahydro-2,4-dioxo-Inosine
go.drugbank.com/drugs/DB04335ApprovedIt is an intermediate in the degradation of purines and purine nucleosides to uric acid and in pathways of purine salvage. It also occurs in the anticodon of certain transfer RNA molecules. … A purine nucleoside that has hypoxanthine linked by the N9 nitrogen to the C1 carbon of ribose.
Synonyms: INO, hypoxanthine D-riboside